Emerging role of botulinum toxin in the management of voiding dysfunction.
about
Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs.Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.Current trends in the evaluation and management of female urinary incontinence.Integrative control of the lower urinary tract: preclinical perspectiveBotulinum toxin in urology: evaluation using an evidence-based medicine approach.The potential and promise of using botulinum toxin in the prostate gland.Developments in pharmacological therapy for the overactive bladder.Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.Botulinum toxin injection: a review of injection principles and protocols.Treatment of overactive bladder syndrome with urethral calibration in women.Botulinum toxin type A for the treatment of lower urinary tract disorders.Botulinum toxin injection for lower urinary tract dysfunction.Intradetrusor injection of botulinum toxin for the management of refractory overactive bladder syndrome: an update.Botulinum toxin treatment for bladder dysfunction.Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections.Neural control of lower urinary tract and targets for pharmacological therapy.Autonomic consequences of spinal cord injury.New intraprostatic injectables and prostatic urethral lift for male LUTS.Treatment of bladder pain syndrome and interstitial cystitis: a systematic review.Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC).Pharmacologic management of non-neurogenic functional obstruction in women.Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy.Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement.The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study.Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.Effects of Dietary Vitamin E Supplementation in Bladder Function and Spasticity during Spinal Cord Injury.Pediatric overactive bladder and lower urinary tract dysfunctions: diagnosis and treatment
P2860
Q33240172-7889766D-41BD-4A17-8D4C-AF8BA5481CD0Q33671401-537025DC-1DEE-48ED-AC66-9CECC72598AAQ35057523-410D6279-38FD-4BF7-846B-366F11AC86F7Q35113508-35F2A839-9725-402E-A633-15992F685BBDQ35545750-924F9F65-3750-4585-AD93-D4A53D814DC3Q36395007-0254AB91-4245-4991-BB8A-54B194163CB6Q36532204-006D7BF3-F8E7-4ECB-8C62-B54A6D6571E9Q36566857-2199993A-901D-49B0-9CF4-805BBBFC8E39Q36737852-E1E5B2FD-C458-4710-99D0-A1BC4C250D97Q36815354-83E646F9-D89C-4752-B973-93674873F1A4Q37230162-E71C6138-9E5D-4A0D-9258-BBB34B5EC561Q37973408-DE5DB61D-CD30-4C85-A981-A54887E415E5Q38008697-0993A486-5680-4AF4-B957-6F05DC8E69BDQ38042228-E8EF1C5A-F955-426A-B5CA-A9DB727E414EQ38103282-216AEEBB-C130-4992-8B3B-3DAEE344A94AQ38205871-80D3C63E-5D8E-4D6D-96C4-B28FFFBA6DB9Q38227058-08219CD6-6F60-4714-8607-0666DC27E0BEQ38271905-F8F7938E-5464-44BF-8F13-DE01B390787AQ38551294-EC96C45B-B80A-488E-8A15-0CECB8C7B5FBQ38566428-081F8DE1-DC6A-4846-BE56-DF3A33305509Q38759710-7C0B50E0-0650-4EE8-B35E-09BF39E5992AQ38812355-CC7600E6-1BAA-4D84-AC29-EFC247041029Q39346432-9F3BBE41-F776-4768-AC0F-FEEF72BB6366Q39825759-0B8AF599-E14F-4D14-9C49-A51A02BC356CQ42160984-4F4EAF07-5445-4C01-8735-5E1C0D4BB726Q43644675-B7F2E363-CC9A-4478-BFFB-2D62063D6DC4Q44393431-F9213ECD-4329-4CBE-91C6-4A4D0C28E7DAQ45370003-FAC857B5-60DC-47DD-AE36-7DBD9908DC93Q46077661-CBDBB32D-1D15-44EE-B975-F05CBFB9D3B3Q47713020-A4835EF7-0320-4B27-B97C-E6A85C3F9327Q48197695-A1286BFC-57FB-4491-808A-27F1DEED7ABBQ48279466-745C8A86-B157-4C60-98A1-55BA72A753E3Q51558644-B047C0A2-B858-4765-8151-3AC7143A3E1AQ52679112-B0453277-F168-46F4-8C53-277694F8D284Q57261042-D94384D2-8E03-42AA-8209-8EF52718D2D4
P2860
Emerging role of botulinum toxin in the management of voiding dysfunction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Emerging role of botulinum toxin in the management of voiding dysfunction.
@ast
Emerging role of botulinum toxin in the management of voiding dysfunction.
@en
type
label
Emerging role of botulinum toxin in the management of voiding dysfunction.
@ast
Emerging role of botulinum toxin in the management of voiding dysfunction.
@en
prefLabel
Emerging role of botulinum toxin in the management of voiding dysfunction.
@ast
Emerging role of botulinum toxin in the management of voiding dysfunction.
@en
P1476
Emerging role of botulinum toxin in the management of voiding dysfunction.
@en
P2093
Christopher P Smith
Michael B Chancellor
P304
P356
10.1097/01.JU.0000127725.48479.89
P407
P433
P577
2004-06-01T00:00:00Z